Purgo Scientific, a pioneering medical device company focused on innovative drug delivery technologies, announced the appointment of James A. Bowman as its new Chief Executive Officer on August 1, 2025. The leadership transition comes as the company advances its flagship platform technology through regulatory development for site-specific drug delivery applications.
Executive Leadership Transition
Bowman succeeds Mike Benjamin, who stepped down as CEO for personal health reasons but will remain actively involved as Chairman of the Board. Under Benjamin's leadership, Purgo established its foundation for growth by advancing the company's lead technology through critical development milestones, securing funding initiatives, and assembling a strong team.
"Jim is exactly the kind of leader we need at this pivotal stage of our growth," said Mike Benjamin, Chairman of the Board. "His proven ability to bring novel surgical and drug delivery technologies to market, combined with a strong track record of operational excellence, makes him an ideal fit to lead Purgo into its next chapter."
New CEO's Background and Experience
Bowman brings over 20 years of experience leading early-stage life science companies and commercializing breakthrough medical and surgical technologies. With a background in biomedical engineering and executive training from Harvard Business School's Owner/President Management program, he combines technical expertise with business acumen and operational leadership.
Throughout his career, Bowman has guided multiple MedTech companies from early-stage innovation to successful commercialization and strategic exits. His experience spans raising venture capital and institutional funding, building high-performing teams, and launching products across diverse medical specialties including general surgery, orthopedics, neurosurgery, cardiothoracic, gynecology, imaging, and oncology.
Platform Technology and Strategic Vision
Purgo Scientific's flagship innovation, currently under regulatory development, represents what the company describes as a new frontier in site-specific drug delivery with applications in both human and veterinary medicine. The platform technology is designed to enhance therapeutic outcomes while reducing systemic side effects through precision drug delivery across multiple clinical indications.
"I'm honored to join Purgo Scientific and build on the strong foundation Mike and the team have created," said Bowman. "With Purgo's unique platform technology and strong scientific underpinnings, we have the opportunity to improve patient outcomes and set a new standard of care in localized therapy."
Future Development Plans
Under Bowman's leadership, the company plans to accelerate product development, build strategic partnerships, and position itself for long-term success in the healthcare market. The focus will be on advancing the localized drug delivery platform through regulatory pathways while exploring applications across multiple therapeutic areas.
